ECONOMIC EVALUATION OF A 100% WHEY-BASED, PARTIALLY HYDROLYZED INFANT FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG FRENCH CHILDREN

Author(s)

Iskedjian M1, Dupont C2, Spieldenner J3, Kanny G4, Raynaud F5, Farah B6, Haschke F31PharmIdeas Research and Consulting Inc., Oakville, ON, Canada, 2Hôpital Saint Vincent de Paul, Paris, France, 3Nestlé Nutrition Institute, Vevey, Switzerland, 4Centre Hospitalier Universitaire de Nancy, Nancy, France, 5Université Paris-Descartes, Paris, France, 6PharmIdeas Research and Consulting Inc., Ottawa, ON, Canada

OBJECTIVES: A pharmacoeconomic analysis was performed to determine costs, consequences and cost-effectiveness of a specific brand of partially hydrolyzed 100% whey formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis (AD) in “at risk” children when compared to standard cow milk formula (CMF) in France. METHODS: An economic model depicting treatment pathways, resource utilization and costs associated with the treatment of AD in healthy “at risk” French newborns who were not exclusively breastfed was constructed for a 12-month time horizon, including an initial six months of formula consumption.  Model inputs were based on the literature, official formularies and expert opinion, including outcomes from a meta-analysis.  The treatment pathways included a dietary management approach, a medical treatment approach and a combination thereof.  The final outcome was the expected cost per avoided case of AD, yielding an incremental cost per avoided case (ICER) of AD for PHF-W vs. CMF.  Outcomes were presented from three perspectives: the French Ministry of Health (MOH), the subject’s family and society (SOC).  A secondary analysis compared PHF-W to extensively hydrolyzed formula (EHF) in prevention. RESULTS: A total of 11,291 AD cases were expected to be avoided by selecting PHF-W over CMF in a birth cohort of 156,649 at risk infants.  The base-case analyses yielded expected ICERs of €2684, -€1474 (savings) and €1210 from the MOH, family and SOC perspectives, respectively. Cost drivers were the formula from the MOH perspectives, time loss from the family perspective, and formula but also to a lesser extent time loss from the SOC perspective.  PHF-W yielded approximately 81M€ savings against EHF in the secondary analysis.  One-way and probabilistic sensitivity analyses confirmed the robustness of the model. CONCLUSIONS: Under a range of assumptions, this analysis has established the cost-effectiveness of PHF-W in the prevention of AD among French infants.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PSS16

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×